Patents by Inventor Esther Zwick-Wallasch

Esther Zwick-Wallasch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heparin-Binding Epidermal Growth Factor-like Growth Factor Binding Proteins
    Publication number: 20160009796
    Abstract: Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.
    Type: Application
    Filed: July 28, 2014
    Publication date: January 14, 2016
    Inventors: ROTHE MIKE, NORBERT PRENZEL, ERIC BORGES, THORE HETTMANN, ESTHER ZWICK-WALLASCH
  • AXL ANTIBODIES
    Publication number: 20150152193
    Abstract: The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.
    Type: Application
    Filed: December 8, 2014
    Publication date: June 4, 2015
    Applicant: U3 PHARMA GMBH
    Inventors: Thore HETTMANN, Jens NIEWOEHNER, Jens RUHE, Peter WIRTZ, Kerstin SELLE, Esther ZWICK-WALLASCH, Mike ROTHE
  • Heparin-Binding Epidermal Growth Factor-like Growth Factor Binding Proteins
    Publication number: 20150056211
    Abstract: Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.
    Type: Application
    Filed: July 28, 2014
    Publication date: February 26, 2015
    Inventors: ROTHE MIKE, NORBERT PRENZEL, ERIC BORGES, THORE HETTMANN, ESTHER ZWICK-WALLASCH
  • COMBINATION OF HB-EGF BINDING PROTEIN AND EGFR INHIBITOR
    Publication number: 20150037336
    Abstract: The present application relates to the combined use of an antigen-binding protein that binds HB-EGF and an EGFR tyrosine kinase inhibitor in medical treatment.
    Type: Application
    Filed: February 20, 2013
    Publication date: February 5, 2015
    Applicant: U3 PHARMA GMBH
    Inventor: Esther Zwick Wallasch
  • AXL antibodies
    Patent number: 8933202
    Abstract: The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: January 13, 2015
    Assignee: U3 Pharma GmbH
    Inventors: Thore Hettmann, Jens Niewöhner, Jens Ruhe, Peter Wirtz, Kerstin Selle, Esther Zwick-Wallasch, Mike Rothe
  • Heparin-binding epidermal growth factor-like growth factor binding proteins
    Patent number: 8828382
    Abstract: Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: September 9, 2014
    Assignees: U3 Pharma GmbH, Amgen Inc.
    Inventors: Mike Rothe, Norbert Prenzel, Eric Borges, Thore Hettmann, Esther Zwick-Wallasch, Orit Foord
  • Heparin-Binding Epidermal Growth Factor-like Growth Factor Binding Proteins
    Publication number: 20110110956
    Abstract: Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.
    Type: Application
    Filed: September 26, 2008
    Publication date: May 12, 2011
    Applicants: AMGEN, INC., U3 PHARMA GMBH
    Inventors: Mike Rothe, Norbert Prenzel, Eric Borges, Thore Hettmann, Esther Zwick-Wallasch, Orit Foord
  • Antibodies directed to the mammalian EAG1 ion channel protein
    Patent number: 7910100
    Abstract: The present invention relates to a particularly advantageous antibody, antibody fragment or derivative thereof, which specifically binds to/interacts with at least one epitope of the extracellular or intracellular domain or the mammalian EAG1 ion channel and to nucleic acid molecules encoding these anti-EAG1 antibodies, antibody fragments or derivatives and to vectors comprising such nucleic acid molecules. The invention additionally relates to methods for the preparation of such anti-EAG1 antibodies, antibody fragments or derivatives thereof, pharmaceutical compositions comprising these antibodies, antibody fragments or derivatives, and methods of using the antibodies, antibody fragments or derivatives or the compositions for a variety of purposes, such as diagnosing disease, treating disease, assessing for the presence of EAG1-expressing cells, or blocking EAG1 function in cells.
    Type: Grant
    Filed: October 4, 2005
    Date of Patent: March 22, 2011
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissen
    Inventors: Walter Stühmer, Hendrik Knötgen, David Gómez-Varela, Luis A. Pardo, Mike Rothe, Esther Zwick-Wallasch, Kerstin Dehne
  • AXL ANTIBODIES
    Publication number: 20100330095
    Abstract: The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.
    Type: Application
    Filed: November 12, 2008
    Publication date: December 30, 2010
    Applicant: U3 PHARMA GMBH
    Inventors: Thore Hettmann, Jens Niewoehner, Jens Ruhe, Peter Wirtz, Kerstin Selle, Esther Zwick-Wallasch, Mike Rothe
  • EGF RECEPTOR TRANSACTIVATION BY G-PROTEIN-COUPLED RECEPTORS REQUIRES METALLOPROTEINASE CLEAVAGE OF proHB-EGF
    Publication number: 20100048684
    Abstract: The present invention relates to agents and methods for growth-factor receptor activation by modulating the G-protein mediated signal transduction pathway.
    Type: Application
    Filed: November 3, 2009
    Publication date: February 25, 2010
    Applicant: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Axel Ullrich, Norbert Prenzel, Esther Zwick-Wallasch, Henrik Daub
  • EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF
    Patent number: 7632645
    Abstract: The present invention relates to agents and methods for growth-factor receptor activation by modulating the G-protein mediated signal transduction pathway.
    Type: Grant
    Filed: December 14, 1999
    Date of Patent: December 15, 2009
    Assignee: Max-Planck-Gesellschaft zur forderung der Wissenschaften e.V.
    Inventors: Axel Ullrich, Norbert Prezel, Esther Zwick-Wallasch, Henrik Daub
  • Novel Antibodies Directed to the Mammalian Eag1 Ion Channel Protein
    Publication number: 20090028851
    Abstract: The present invention relates to a particularly advantageous antibody, antibody fragment or derivative thereof, which specifically binds to/interacts with at least one epitope of the extracellular or intracellular domain or the mammalian EAG1 ion channel and to nucleic acid molecules encoding the same and to vectors comprising said nucleic acid molecules. The invention additionally relates to methods for the preparation of said antibody, antibody fragments or derivatives thereof and to pharmaceutical compositions comprising the same. Furthermore, the use of said antibody, antibody fragment or derivative thereof and also diagnostic compositions comprising said components are disclosed in the specification. The invention also relates to a method of assessing for the presence of EAG1 expressing cells and for a method of blocking EAG1 function in said cells. The invention further relates to a method of treating diseases with the help or said antibody or antibody fragment or derivative thereof.
    Type: Application
    Filed: October 4, 2005
    Publication date: January 29, 2009
    Applicants: MAXPLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCH, U3 PHARMA AG
    Inventors: Walter Stuhmer, Hendrik Knotgen, David Gomez-Varela, Luis A. Pardo, Mike Rothe, Esther Zwick-Wallasch, Kerstin Dehne